secwatch.observer — SEC 8-K summary
======================================

Issuer:     AGIOS PHARMACEUTICALS, INC. (AGIO)
CIK:        0001439222
Form:       8-K
Filed at:   2022-10-07T23:59:59+00:00
Accession:  0001193125-22-259591
Event type: other
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Agios amends severance plan; expands C-Level definition, alters equity vesting rules
--------------------------------------------------------------------------------

- C-Level Employee definition expanded to include any job title above Senior Vice President.
- New-Hire Equity Awards granted after October 6, 2022 will have accelerated vesting on non-Change-of-Control termination or death/disability.
- Change-of-Control Termination now triggers full vesting of service-based equity awards; performance awards per original plan terms.
- Post-Change-of-Control amendment/termination restriction period increased from 12 to 18 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1439222/000119312522259591/0001193125-22-259591-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1439222/000119312522259591/d363139d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-259591

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer